General Information of Drug Transporter (DT)
DT ID	DTD0071 Transporter Info
Gene Name	ABCG1
Protein Name	ATP-binding cassette sub-family G member 1
Gene ID	9619
UniProt ID	P45844
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs225440
Site of GPD	chr21:42232943 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.4295/2151 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotype CC)		[ 1]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotype CC)		[ 1]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased neutropenia risk in patients (compare with genotype CC)		[ 1]
Fluorouracil	N.A.	Neutropenia	Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Irinotecan	N.A.	Neutropenia	Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Leucovorin	N.A.	Neutropenia	Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Fluorouracil	N.A.	Colorectal Neoplasms	Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.		[ 1]
Genetic Polymorphism	rs425215
Site of GPD	chr21:42286991 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	C=0.4320/854 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Drug Toxicity	Genotype GG is associated with increased likelihood of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes CC + CG.		[ 2]
Genetic Polymorphism	rs182694
Site of GPD	chr21:42278705 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.3450/682 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Citalopram	N.A.	Drug Toxicity	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 3]
Fluoxetine	N.A.	Drug Toxicity	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 3]
Paroxetine	N.A.	Drug Toxicity	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 3]
Sertraline	N.A.	Drug Toxicity	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.		[ 3]
Genetic Polymorphism	rs492338
Site of GPD	chr21:42281867 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.5250/1038 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotype AA is not associated with risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype GG.		[ 4]
References
1	ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2015 Dec;25(12):573-83.
2	Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther. 2011 Nov 01;12(9):780-7.
3	ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics. 2013 Nov;14(14):1723-30.
4	Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat. 2014 May;145(1):245-54.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.